SCHEMBL21782826

SCHEMBL21782826

C=Cc1c(/C=C\C)[nH]c(=O)n1C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.32
YTHDF2 Q9Y5A9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493207 0.86 CSNK2A2 (0.31) LMNA
SCHEMBL18975821 0.78 ADORA2A (0.33) LMNA
SCHEMBL13910839 0.76
SCHEMBL19149051 0.67 TYMP (0.39)
SCHEMBL18535906 0.67 CA12 (0.32)
SCHEMBL24557630 0.66
SCHEMBL18976325 0.65 TYMP (0.36)
SCHEMBL19706341 0.63 TYMP (0.30)
SCHEMBL23510010 0.63
SCHEMBL19998844 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023133457-A1 NOVEL KALIRIN INHIBITORS FOR REGULATION OF SYNAPTIC PLASTICITY AND NEUROPATHIC PAIN TREATMENT NORTHWESTERN UNIVERSITY (US) 2023-07-13 WO disclosed
EP-3617330-A1 BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS Genentech, Inc. (US) 2020-03-04 EP disclosed